<DOC>
	<DOCNO>NCT00028535</DOCNO>
	<brief_summary>Phase I trial study effectiveness interleukin-12 , paclitaxel , trastuzumab treat patient solid tumor . Interleukin-12 may kill tumor cell stop blood flow tumor stimulate person 's white blood cell kill cancer cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Monoclonal antibody trastuzumab locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Combining interleukin-12 , chemotherapy , monoclonal antibody therapy may kill tumor cell .</brief_summary>
	<brief_title>Interleukin-12 , Paclitaxel , Trastuzumab Treating Patients With Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose interleukin-12 give combination paclitaxel trastuzumab ( Herceptin® ) patient HER2/neu-overexpressing malignancy . II . Determine response rate time progression patient treat regimen . III . Determine anti-tumor effect regimen patient . OUTLINE : This dose-escalation study interleukin-12 . Patients receive trastuzumab ( Herceptin® ) IV 30-90 minute day 1 , 8 , 15 paclitaxel IV 3 hour day 1 course 1 . Beginning course 2 , patient receive trastuzumab paclitaxel course 1 interleukin-12 subcutaneously day 2 , 5 , 9 , 12 , 16 , 19 . Courses repeat every 21 day 1 year absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos interleukin-12 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients follow every 3 month 1 year every 6 month thereafter .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms , Male</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Interleukin-12</mesh_term>
	<criteria>Histologically confirm HER2/neuoverexpressing ( 2+ 3+ ) malignancy standardize assay ( fluorescence insitu hybridization allow ) Measurable evaluable disease Failed standard curative therapy No brain CNS metastasis Hormone receptor status : Not specify Male female Performance status Karnofsky 70100 % At least 6 month Absolute neutrophil count least 1,500/mm^3 Hemoglobin least 8 g/dL ( transfusion epoetin alfa allow ) Platelet count least 100,000/mm^3 Bilirubin great 1.5 time upper limit normal ( ULN ) AST ALT great 3.0 time ULN Hepatitis B surface antigen negative Creatinine great 1.5 time ULN Calcium great 11 mg/dL ( calciumlowering agent allow ) No active unstable cardiovascular disease No cardiac disease require drug device intervention No coronary artery disease No congestive heart failure Cardiac ejection fraction normal echocardiogram MUGA scan No significant peripheral neuropathy No significant CNS disease Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No serious concurrent infection require IV antibiotic therapy No clinically significant autoimmune disease ( e.g. , rheumatoid arthritis ) No clinically significant gastrointestinal bleeding No uncontrolled peptic ulcer disease No inflammatory bowel disease No major illness would preclude study participation No concurrent malignancy except nonmelanoma skin cancer carcinoma situ cervix No prior interleukin12 No prior trastuzumab ( Herceptin® ) At least 3 week since prior chemotherapy At least 3 week since prior hormonal therapy No concurrent systemic corticosteroid At least 3 week since prior radiotherapy At least 3 week since prior surgery At least 3 week since prior investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>